We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego
News

High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego

High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego
News

High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

High Throughput Genomics, Inc. has announced a collaboration agreement with the University of California, San Diego, Department of Medicine, Division of Endocrinology and Metabolism.

Under the terms of the agreement, HTG and UCSD will collaborate to generate arrays using tissue samples from mice as well as various cell lysates to evaluate genes responsible for inflammation and insulin production using HTG’s qNPA™ quantitative Nuclease Protection Assay technology. Dr. Jerry Olefsky is the lead collaborator on the project for UCSD.

One of the key goals for this research program is to study mechanisms of insulin resistance and how inflammation is involved in the pathogenesis of diabetes. Having genes on the array that are markers for inflammation is an effective way for UCSD to assess biomarkers and study the genes in question.

“We are excited about the utility of HTG’s technology platform for a number of reasons including cost effectiveness and time savings by having multiple genes analyzed simultaneously,” said Dr. Jerry Olefsky. “The reliability and reproducibility of the technology will enable our research team to move through our project with great ease and confidence.”

HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.

Advertisement